Carl-Henrik Heldin
From Wikipedia, the free encyclopedia
Carl-Henrik Heldin (born 9 August 1952) is Chairman of the Board for the Nobel Foundation, and a molecular biologist and medical researcher. He has been director of the Uppsala branch of Ludwig Cancer Research since 1986 and professor in molecular cell biology at the medical faculty of Uppsala University since 1992. He is vice-president of the European Research Council since 2011[1] and was appointed chairman of the Nobel Foundation in 2013.[2][3]
His research has focused on the mechanisms of signal transduction by growth regulatory factors like platelet-derived growth factor (PDGF) and transforming growth factor (TGF).
He was senior editor of Cancer Research from 2003 to 2009.[4]
He is a member of the following learned societies
- 1989 European Molecular Biology Organization.
- 1991 Royal Swedish Academy of Sciences.[5][6]
- 1999 Academia Europaea.
- 2002 Japanese Association for Cancer Research.
- 2006 Finnish Society of Sciences and Letters.[7]
- 2006 Scan Balt Academy
- 2007 Hellenic Biochemical Society
- 2009 Norwegian Academy of Science and Letters
- 2009 European Academy of Cancer Sciences
He is honorary doctor of University of Patras, University of Helsinki, University of Turku and University of Heidelberg.[6]
